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Abstract The molecular structures of drug target proteins and receptors form the basis for 
'rational' or structure guided drug design. The majority of target structures are experimentally 
determined by protein X-ray crystallography, which as evolved into a highly automated, high 
throughput drug discovery and screening tool. Process automation has accelerated tasks from 
parallel protein expression, fully automated crystallization, and rapid data collection to highly 
efficient structure determination methods. A thoroughly designed automation technology 
platform supported by a powerful informatics infrastructure forms the basis for optimal 
workflow implementation and the data mining and analysis tools to generate new leads from 
experimental protein drug target structures.  
Keywords:  High throughput crystallography, drug discovery, fragment screening. 
 
1. The role of structure based methods in drug discovery 
Traditional assay based high throughput compound screening (HTS), well established in 
pharmaceutical R&D, covers compound diversity largely by combinatorial exploration of the 
chemical space and/or by screening of natural compound libraries [1].Typically, millions of 
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compounds are screened in high density format against a protein target or receptor, at a cost of 
several dollars per assay and compound. In addition to the relatively high cost, the detailed 
nature of the target- lead affinity is difficult to identification with biochemical techniques only. 
Structure-based techniques such as Nuclear Magnetic Resonance (NMR) screening and High 
Throughput Protein Crystallography [2]  (HTPX) enable a more rational and targeted approach 
to lead discovery and optimization. By avoiding the complexity of target structure determination, 
modern ligand-based high-field NMR- based screening can de facto achieve throughput of 
several thousand ligand interactions per day. The additional attractiveness of drug target X-ray 
crystallography is the fact that the method yields highly detailed structural information of the 
protein target complexed with its ligand, which has been highly valued for structure guided lead 
optimization in later stages of preclinical drug development. With recent advances in automated 
high throughput protein crystallography, the major obstacles to using structure based methods in 
early stages of drug discovery as a screening tool have been overcome: First, a diffracting protein 
crystal needs to be produced - a task that can prove challenging and often can only be achieved 
after substantial protein engineering - and then a full structure refinement for each target- ligand 
complex structure is necessary.  
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Figure 1 Elements of crystallographic structure determination. In the right hand flow diagram, highlights 
indicate process steps with high dependence on advanced robotic automation. Structure determination, validation 
and analysis are conducted in silico  and already highly automated (image reproduced with permission from GIT 
publications, Germany).     
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2. High throughput X-ray crystallography in drug lead discovery 
Historically, protein structures have been determined by an expert in laborious cycles of 
repeated manual rebuilding of the structure models into electron density and subsequent 
refinement. With the advance of automated protein purification and crystallization techniques 
and powerful phasing and model building methods [3], determination of a target- ligand complex 
can now be accomplished in a nearly automatic mode. The resulting rapid availability of ligand-
complex crystal structures via HTPX enables novel strategies of crystallographic fragment 
screening and fragment evolution [4]. Protein targets are co-crystallized with smaller molecules 
of a fragment library, where high concentrations of ligands allow discovery of weaker binders, 
starting with affinities in the low mM range. In contrast, classical, bioassay based HT compound 
screening focuses on initial high affinity hits of already drug- like molecules in the nano-molar 
range, 
Fragment libraries are developed to either allow classical combinatorial chemistry, or to 
support novel methods such as in-situ click chemistry between fragments [4].  From crystal 
structures of fragments located in the binding pocket of the target, larger molecules with higher 
binding affinities can be assembled, and the process of fragment-evolution repeated. Starting 
from a collection of relatively few, low affinity, low-molecule weight fragments, a targeted, 
structure based evolution of molecules with increased drug like properties and low nM affinity 
can be achieved in few steps. Crystallographic library fragments generally follow a 'rule of 3' [5], 
similar to Lipinski's 'rule of 5' for drug- like properties. During the design process, ADME/T 
properties, cross-reactivity with other targets, metabolites and drugs can be predicted already in 
silico, thus increasing the chance to arrive at a successful drug candidate.                        
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Figure 2 Example for exploration of X-ray structures in drug discovery. A surface charge representation of a 
Mycobacterium tuberculosis target molecule  (PDB entry 1W30), with a lead compound fragment docked in silico by 
HT virtual ligand screening.   
3. Drug target structures as a basis for virtual ligand screening 
The value of fully detailed structural information extends beyond the obvious goal of 
ligand screening and lead optimization. Knowledge of the structure of a potential drug target per 
se, even without a ligand, informs about the drugability of the target. An array of structural 
bioinformatics tools can be deployed early on, to screen in silico for properties of a protein that 
indicate its suitability as a drug target [6]. Similar to experimental fragment screening, in silico 
virtual ligand and fragment screening (VLS) can be used on the native target structure to identify 
a smaller, target-specific subset of effective compounds [7]. Although in early stages virtual 
screening struggled to meet its initial promise and drug discovery remained dominated by 
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empirical screening, recent successes in predicting new ligands and their receptor-bound 
structures [1] and better rates of ligand discovery compared to empirical screening, have led to 
widespread use of VLS in drug discovery to compliment empirical screening [8]. Additional 
attractiveness is the early inclusion of drug-likeness and ADME/T data in the ranking of the 
compounds, thus providing early indications that a lead may fail in later drug development stages 
[9]. 
4. Automation in high throughput protein crystallography 
Synergistic developments in technology, in particular laboratory automation, cryo-, 
synchrotron-, and computational techniques, combined with influx of substantial public and 
venture capital funding, have made HTPX possible. Given the potentially enormous rewards of 
structure guided drug development [2], it is not surprising that commercial biotech ventures have 
been able to attract funds to develop and implement advanced  robotic HTPX pipelines. Public 
funding of structural genomics pilot projects in the USA and similar efforts in Europe, Japan and 
Israel (http://www.isgo.org/ lists all SG initiatives world wide), provide the means for 
development of non-proprietary high throughput structure determination methods, which has 
benefited not only drug discovery, but practically every structural biology effort. 
4.1. Task-centric and data-centric process analysis.  
The process of crystallographic structure determination can be broken up into a number 
of successive task blocks (Figure 3). A large number of these tasks are successive screening 
experiments, each creating a substantial and rapidly multiplying amount of data. As these data 
form the basis for knowledge discovery, predictive modelling, and process optimization - thus 
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translating directly into intellectual property - the importance of a data-centric view 
complementing the robotic automation of the various tasks can hardly be overstated [10].  
The highest demand for task automation is generally found in screening steps, where 
repetitive operations of modest complexity can be conveniently handled by robotics.  Protein 
crystallization is currently the most prominent candidate for full automation, while at the same 
time the front-end of protein production begins to undergo a similar transformation with 
increasing use of small scale, high throughput parallel expression and purification screening 
techniques [11]. Novel plasmid vectors, expression autoinduction, affinity- tagged proteases of 
high specificity, and modular parallel chromatography equipment have contributed major 
advances towards automation in protein production. Structure solution, model building and 
refinement on the other hand are conducted entirely in silico, and given the rapid development of 
automated computational crystallography are generally not considered throughput limiting 
factors.     
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Figure 3 Basic tasks in automated protein crystallization. Shading indicates: basic liquid handling (magenta); 
crystallization plate setup and handling (yellow); and mounting and data collation tasks (cyan). Omitted for clarity 
are the numerous feedback pathways from structure analysis to target modification and in iterative ligand screening 
and optimization.  
One of the most substantial advantages of automation is miniaturization, allowing 
comprehensive parallel screening of large sample sets (multiple constructs, orthologs) with very 
little material. As a consequence, statistically sound go/no-go decisions can be made early in 
each successive screening step, and the pursuit of a target already showing warning signs of 
limited likelihood of success can be avoided. Early go/no-go decisions are common practice in 
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pharmaceutical industry, as failures in later stages of the process (exemplified by losing 
harvestable crystals or the failure of new therapeutic drug candidates in late phases of clinical 
trials) become increasingly costly.  
Full walk-away automation up to but not including harvesting is conceivable given the 
current equipment on the market, and has been demonstrated (albeit at substantial cost) in several 
custom-made industrial designs [12]. Cocktail preparation, plate setup, automated crystal 
recognition, and subsequent optimization can be integrated with plate handling robotics and 
provide no principal (nonetheless financial) challenges. Process automation currently stops at the 
harvesting stage, largely due to the expense of micromanipulation, and the need for rather 
advanced machine vision tools to allow real- time processing of the events during crystal 
harvesting. However, reproducibly manufactured mounting loop designs and micro-manipulation 
actuators for robots are being developed [13], and will eventually address this remaining manual 
bottleneck. Once the crystals are safely cryo-protected, however, robotic mounting of sample 
pins has become standard on HTPX synchrotron beam lines [14] and in larger biotech companies 
and laboratories. 
4.2. Data processing and handling 
An often underestimated consequence of task automation is the rapid generation of data 
during multiple levels of successively branched screening steps such as expression, 
solubilization, crystallization, cryo-protection (figure 4). Despite considerable sample attrition, 
the amount of data generated at each screening step can rapidly outstrip the capability to analyse 
them. Consequently, even for a small effort, capturing of primary data at the source, directly into 
a relational data base via automated scripts or a laboratory information management system 
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(LIMS), is important. In addition, with increasing automation, tightly integrated process control, 
multiple feedback steps, real time data processing and decision making, and machine learning for 
predictive purposes [15] are becoming major components of any automation intensive 
laboratory. Direct capture of all experiments also assures the collection of negative experimental 
results, a valuable and necessary component in the analysis of complex and multivariate 
crystallization data [16, 17].   
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Figure 4 Path through a basic 3-step screening tree in a protein production and crystallization laboratory. Despite 
substantial attrition, the amount of data multiplies rapidly [18] with each screening step, and an adequate IT 
infrastructure must be provided for data capture, data analysis and machine learning, with tight integration to 
process control and process refinement. Figure reproduced from [15]. 
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5. Summary 
High throughput crystallization of even a few proteins per day is not sustainable without 
careful planning of the entire automation setup and thorough operations review. A singular 
deployment of high speed robotics, in particular if intended to significantly increase throughput, 
will likely create new bottlenecks downstream. Data capture, warehousing and curating is of 
substantial importance not just for process control, but also for successful data mining of highly 
dimensional and complex proteomics data. Realistic planning and full consideration of high 
throughput process and design principles will go a long way to accomplish a successful and 
financially sound transition into robotic high throughput screening.    
Given a well conceived and implemented design, protein drug target crystallography can 
be implemented efficiently and has become an increasingly attractive drug discovery and 
screening tool, allowing in unprecedented ways novel strategies that identify lead candidates 
early. Structural information combined with in silico approaches provides a powerful basis for 
corrective action during design and optimization of drug candidates - before more resources are 
expended on low probability targets likely to fail in later steps.  
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